Andrew Komjathy is Chief Commercial Officer at Astria Therapeutics, Inc. (ATXS). They have made 1 open-market trade across 1 company since 2021, most recently 2026-01-23.
CIK 0001788465
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $670 since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATXS | 100 | $1K |
Shares reported on the most recent Form 4, priced at the 2021-11-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATXS | BUY | 2021-11-19 | 2021-11-23 | $6.70 | $670 | -15.1% | -14.0% | +0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.